Bacterial Vaginosis Treatment Guidelines

Introduction to Treatment

The CDC guidelines state that patients allergic to oral metronidazole should not be administered metronidazole vaginally, due to cross-reactivity 1
Bacterial vaginosis (BV) diagnosis requires confirming clinical criteria, which includes three of the following: homogeneous discharge, clue cells, vaginal fluid pH greater than 4.5, and a positive whiff test, as recommended by the CDC 1, 2

The CDC recommends several equally effective first-line treatment options, including:

Treatment	Regimen
Metronidazole	500 mg orally twice daily for 7 days
Metronidazole gel	0.75%, one full applicator (5g) intravaginally once daily for 5 days
Clindamycin cream	2%, one full applicator (5g) intravaginally at bedtime for 7 days

Clindamycin 300 mg orally twice daily for 7 days is recommended for patients allergic to metronidazole, including pregnant patients 1
Clindamycin cream has demonstrated cure rates of 82%, comparable to the 78% cure rate of oral metronidazole in controlled trials 1
Metronidazole 500 mg orally twice daily for 7 days has a 95% cure rate, while metronidazole 2 g orally in a single dose has an 84% cure rate, according to the Centers for Disease Control and Prevention 2
Clindamycin cream 2% applied intravaginally at bedtime for 7 days is the preferred treatment for BV during the first trimester, as recommended by the American College of Family Physicians 4, 3
Metronidazole is contraindicated during the first trimester of pregnancy, but may be safely used after the first trimester, according to CDC guidelines and FDA labeling 2
Amoxicillin-clavulanic acid is an alternative safe option during pregnancy, according to the American Gastroenterological Association 5

Clindamycin cream has minimal systemic absorption, with approximately 4% bioavailability 1
Clindamycin cream is associated with fewer systemic side effects compared to oral medications 1
Metronidazole can cause gastrointestinal disturbances, metallic taste, disulfiram-like reaction with alcohol, and potential for peripheral neuropathy with prolonged use, as reported by the medical literature 6
Patients using metronidazole should avoid alcohol during treatment and for 24 hours afterward to prevent disulfiram-like reactions, as advised by the CDC 1, 2, 3

Treatment is particularly important for high-risk pregnant women, as bacterial vaginosis is associated with adverse pregnancy outcomes, including premature rupture of membranes, preterm labor and birth, postpartum endometritis, and chorioamnionitis, as reported by the American College of Family Physicians 4, 3
Untreated BV in pregnancy increases the risk of preterm birth, low birth weight, and chorioamnionitis, as reported by the American College of Family Physicians 4, 3
The American College of Obstetricians and Gynecologists recommends screening and treating high-risk asymptomatic pregnant women (history of previous preterm birth) for BV, preferably in the early second trimester, to reduce preterm delivery in this population, with moderate strength of evidence 3, 1

Routine treatment of sex partners is not recommended, as clinical trials indicate that partner treatment does not affect a woman's response to therapy or likelihood of relapse/recurrence, according to the CDC, with a high strength of evidence 3, 1
Follow-up visits are not necessary if symptoms resolve, according to the CDC 2, 3
Follow-up evaluation 1 month after treatment completion is recommended for pregnant women to ensure treatment effectiveness, as suggested by the American College of Family Physicians 3
BV recurrence is common, with 50-80% of women experiencing recurrence within a year of treatment, emphasizing the need for regular follow-up evaluations 3
Another recommended treatment regimen different from the initial one should be used for recurrent BV, as recommended by the CDC 3
Patients should abstain from sexual intercourse until they complete their full course of BV treatment to minimize the risk of reinfection and ensure treatment effectiveness, as recommended by the Centers for Disease Control and Prevention (CDC) 1, 7